Tissue microarrays: emerging standard for biomarker validation

Current Opinion in Biotechnology

Volumn 19, Issue 1, 2008, Pages 19-25

  Hassan, Saima ^a   Ferrario, Cristiano ^a   Mamo, Aline ^a   Basik, Mark ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; DNA SEQUENCES; RNA; TISSUE CULTURE;

BIOMARKER VALIDATION; DNA MICROARRAYS;

MICROARRAYS;

BIOLOGICAL MARKER;

DATA ANALYSIS; DNA MICROARRAY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SCORING SYSTEM; STANDARD; TISSUE MICROARRAY;

BIOLOGICAL MARKERS; DATA INTERPRETATION, STATISTICAL; HUMANS; MICROARRAY ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTEIN ARRAY ANALYSIS;

EID: 38949127290     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2007.10.009     Document Type: Review

References (49)

1. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., Torhorst J., Mihatsch M.J., Sauter G., and Kallioniemi O.P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 (1998) 844-847
2. Aguilar-Mahecha A., Hassan S., Ferrario C., and Basik M. Microarrays as validation strategies in clinical samples: tissue and protein microarrays. Omics 10 (2006) 311-326
3. Kallioniemi O.P., Wagner U., Kononen J., and Sauter G. Tissue microarray technology for highthroughput molecular profiling of cancer. Hum Mol Genet 10 (2001) 657-662
4. Salvucci O., Bouchard A., Baccarelli A., Deschenes J., Sauter G., Simon R., Bianchi R., and Basik M. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 97 (2006) 275-283
5. Sawada K., Radjabi A.R., Shinomiya N., Kistner E., Kenny H., Becker A.R., Turkyilmaz M.A., Salgia R., Yamada S.D., Vande Woude G.F., et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67 (2007) 1670-1679
6. Makretsov N.A., Huntsman D.G., Nielsen T.O., Yorida E., Peacock M., Cheang M.C., Dunn S.E., Hayes M., van de Rijn M., Bajdik C., et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10 (2004) 6143-6151
7. Jacquemier J., Ginestier C., Rougemont J., Bardou V.J., Charafe-Jauffret E., Geneix J., Adelaide J., Koki A., Houvenaeghel G., Hassoun J., et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65 (2005) 767-779
8. Abd El-Rehim D.M., Ball G., Pinder S.E., Rakha E., Paish C., Robertson J.F., Macmillan D., Blamey R.W., and Ellis I.O. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116 (2005) 340-350
9. Diallo-Danebrock R., Ting E., Gluz O., Herr A., Mohrmann S., Geddert H., Rody A., Schaefer K.L., Baldus S.E., Hartmann A., et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res 13 (2007) 488-497
10. Shi T., Seligson D., Belldegrun A.S., Palotie A., and Horvath S. Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol 18 (2005) 547-557
11. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
12. Kim H.L., Seligson D., Liu X., Janzen N., Bui M.H., Yu H., Shi T., Figlin R.A., Horvath S., and Belldegrun A.S. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10 (2004) 5464-5471
13. Ring B.Z., Seitz R.S., Beck R., Shasteen W.J., Tarr S.M., Cheang M.C., Yoder B.J., Budd G.T., Nielsen T.O., Hicks D.G., et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3039-3047
14. Dolled-Filhart M., Ryden L., Cregger M., Jirstrom K., Harigopal M., Camp R.L., and Rimm D.L. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 12 (2006) 6459-6468. Using genetic algorithms, the authors were able to identify a prospectively assignable score to a cluster of biomarkers that was able to prognosticate patients.
15. Lambros M.B., Natrajan R., and Reis-Filho J.S. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 38 (2007) 1105-1122
16. Holst F., Stahl P.R., Ruiz C., Hellwinkel O., Jehan Z., Wendland M., Lebeau A., Terracciano L., Al-Kuraya K., Janicke F., et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39 (2007) 655-660. This is the first report of a TMA being used in the discovery of a novel gene amplification in cancer tissue.
17. Brown L.A., and Huntsman D. Fluorescent in situ hybridization on tissue microarrays: challenges and solutions. J Mol Histol 38 (2007) 151-157
18. Seil I., Frei C., Sultmann H., Knauer S.K., Engels K., Jager E., Zatloukal K., Pfreundschuh M., Knuth A., Tseng-Chen Y., et al. The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. Int J Cancer 120 (2007) 2635-2642
19. Rodriguez-Pinilla M., Rodriguez-Peralto J.L., Hitt R., Sanchez J.J., Ballestin C., Diez A., Sanchez-Verde L., Alameda F., and Sanchez-Cespedes M. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Clin Cancer Res 10 (2004) 8486-8492
20. Ryden L., Stendahl M., Jonsson H., Emdin S., Bengtsson N.O., and Landberg G. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res Treat 89 (2005) 135-143
21. Jubb A.M., Hurwitz H.I., Bai W., Holmgren E.B., Tobin P., Guerrero A.S., Kabbinavar F., Holden S.N., Novotny W.F., Frantz G.D., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24 (2006) 217-227
22. Cheang M.C., Treaba D.O., Speers C.H., Olivotto I.A., Bajdik C.D., Chia S.K., Goldstein L.C., Gelmon K.A., Huntsman D., Gilks C.B., et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24 (2006) 5637-5644
23. Fitzgibbons P.L., Murphy D.A., Dorfman D.M., Roche P.C., and Tubbs R.R. Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. Arch Pathol Lab Med 130 (2006) 1440-1445. The authors demonstrated the inter-laboratory validation of HER2 staining in TMAs, offering a quality control for individual laboratories.
24. Moskaluk C.A., and Stoler M.H. Agarose mold embedding of cultured cells for tissue microarrays. Diagn Mol Pathol 11 (2002) 234-238
25. Andersson A.C., Stromberg S., Backvall H., Kampf C., Uhlen M., Wester K., and Ponten F. Analysis of protein expression in cell microarrays: a tool for antibody-based proteomics. J Histochem Cytochem 54 (2006) 1413-1423. This is a detailed discussion of the technique to create a cell microarray.
26. Ferrer B., Bermudo R., Thomson T., Nayach I., Soler M., Sanchez M., Castillo M., Calvo J., Campo E., and Fernandez P.L. Paraffin-embedded cell line microarray (PECLIMA): development and validation of a high-throughput method for antigen profiling of cell lines. Pathobiology 72 (2005) 225-232
27. Liu Y.J., Yan P.S., Li J., and Jia J.F. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol 11 (2005) 6601-6606
28. Korabiowska M., Bauer H., Quentin T., Stachura J., Cordon-Cardo C., and Brinck U. Application of new in situ hybridization probes for Ku70 and Ku80 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemical analysis. Hum Pathol 35 (2004) 210-216
29. Cox M.L., Schray C.L., Luster C.N., Stewart Z.S., Korytko P.J., Khan K.N.M., Paulauskis J.D., and Dunstan R.W. Assessment of fixatives, fixation, and tissue processing on morphology and RNA integrity. Exp Mol Pathol 80 (2006) 183-191
30. Schoenberg Fejzo M., and Slamon D.J. Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol 159 (2001) 1645-1650
31. Zhou L., Hodeib M., Abad J.D., Mendoza L., Kore A.R., and Hu Z. New tissue microarray technology for analyses of gene expression in frozen pathological samples. Biotechniques 43 (2007) 101-105
32. Elstner E., Muller C., Koshizuka K., Williamson E.A., Park D., Asou H., Shintaku P., Said J.W., Heber D., and Koeffler H.P. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 95 (1998) 8806-8811
33. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
34. Giltnane J.M., and Rimm D.L. Technology insight: identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 1 (2004) 104-111
35. Dolled-Filhart M., McCabe A., Giltnane J., Cregger M., Camp R.L., and Rimm D.L. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66 (2006) 5487-5494
36. Giltnane J.M., Ryden L., Cregger M., Bendahl P.O., Jirstrom K., and Rimm D.L. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol 25 (2007) 3007-3014
37. Altman D.G., Lausen B., Sauerbrei W., and Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86 (1994) 829-835
38. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., and Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97 (2005) 1180-1184
39. Camp R.L., Dolled-Filhart M., and Rimm D.L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10 (2004) 7252-7259
40. Uhlen M. Mapping the human proteome using antibodies. Mol Cell Proteomics 6 (2007) 1455-1456
41. Moch H., Schraml P., Bubendorf L., Richter J., Gasser T.C., Mihatsch M.J., and Sauter G. Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization. Cancer Res 58 (1998) 2304-2309
42. Sauter G., and Mirlacher M. Tissue microarrays for predictive molecular pathology. J Clin Pathol 55 (2002) 575-576
43. Rosen D.G., Huang X., Deavers M.T., Malpica A., Silva E.G., and Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17 (2004) 790-797
44. Pacifico M.D., Grover R., Richman P., Daley F., and Wilson G.D. Validation of tissue microarray for the immunohistochemical profiling of melanoma. Melanoma Res 14 (2004) 39-42
45. Salto-Tellez M., Nga M.E., Han H.C., Wong A.S., Lee C.K., Anuar D., Ng S.S., Ho M., Wee A., Chan Y.H., et al. Tissue microarrays characterise the clinical significance of a VEGFA protein expression signature in gastrointestinal stromal tumours. Br J Cancer 96 (2007) 776-782
46. Chiesa-Vottero A.G., Rybicki L.A., and Prayson R.A. Comparison of proliferation indices in glioblastoma multiforme by whole tissue section vs tissue microarray. Am J Clin Pathol 120 (2003) 902-908
47. Torhorst J., Bucher C., Kononen J., Haas P., Zuber M., Kochli O.R., Mross F., Dieterich H., Moch H., Mihatsch M., et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159 (2001) 2249-2256
48. Zhang D., Salto-Tellez M., Do E., Putti T.C., and Koay E.S. Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34 (2003) 362-368
49. Egervari K., Szollosi Z., and Nemes Z. Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract 203 (2007) 169-177